

Erin E Mulvihill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4301769/publications.pdf>

Version: 2024-02-01

43
papers

2,771
citations

257450

24
h-index

254184

43
g-index

43
all docs

43
docs citations

43
times ranked

4219
citing authors

#	ARTICLE	IF	CITATIONS
1	Open chromatin state of Dpp4 with glucocorticoid treatment -setting up shop for metasteroid diabetes?. <i>Endocrinology</i> , 2022, 163, .	2.8	1
2	Islet Biology During COVID-19: Progress and Perspectives. <i>Canadian Journal of Diabetes</i> , 2022, 46, 419-427.	0.8	2
3	Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials. <i>Diabetes</i> , 2022, 71, 173-183.	0.6	13
4	Quantification of murine myocardial infarct size using 2-D and 4-D high-frequency ultrasound. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2022, 322, H359-H372.	3.2	7
5	Nobiletin Prevents High-Fat Diet-Induced Dysregulation of Intestinal Lipid Metabolism and Attenuates Postprandial Lipemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 127-144.	2.4	21
6	14-3-3 β Constrains insulin secretion by regulating mitochondrial function in pancreatic β^2 cells. <i>JCI Insight</i> , 2022, 7, .	5.0	11
7	Hmgcs2-mediated ketogenesis modulates high-fat diet-induced hepatosteatosis. <i>Molecular Metabolism</i> , 2022, 61, 101494.	6.5	28
8	miR-223 Exerts Translational Control of Proatherogenic Genes in Macrophages. <i>Circulation Research</i> , 2022, 131, 42-58.	4.5	17
9	Guidelines on models of diabetic heart disease. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2022, 323, H176-H200.	3.2	20
10	Dansyl-NA3 conjugates for glycoprotein detection through fluorescent tagging and native gel electrophoresis. <i>New Journal of Chemistry</i> , 2021, 45, 13185-13195.	2.8	1
11	Size-adjusted aortic valve area: refining the definition of severe aortic stenosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 1142-1148.	1.2	6
12	Citrulline supplementation improves glucose and exercise tolerance in obese male mice. <i>Experimental Physiology</i> , 2020, 105, 270-281.	2.0	11
13	Myeloid deletion and therapeutic activation of AMPK do not alter atherosclerosis in male or female mice. <i>Journal of Lipid Research</i> , 2020, 61, 1697-1706.	4.2	6
14	Islet Health, Hormone Secretion, and Insulin Responsivity with Low-Carbohydrate Feeding in Diabetes. <i>Metabolites</i> , 2020, 10, 455.	2.9	7
15	The gut hormone receptor GIPR links energy availability to the control of hematopoiesis. <i>Molecular Metabolism</i> , 2020, 39, 101008.	6.5	12
16	Plasma Myokine Concentrations After Acute Exercise in Non-obese and Obese Sedentary Women. <i>Frontiers in Physiology</i> , 2020, 11, 18.	2.8	29
17	Pimozide Alleviates Hyperglycemia in Diet-Induced Obesity by Inhibiting Skeletal Muscle Ketone Oxidation. <i>Cell Metabolism</i> , 2020, 31, 909-919.e8.	16.2	37
18	Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2020, 13, 117955142091297.	1.9	48

#	ARTICLE	IF	CITATIONS
19	Hematopoietic cell-derived versus enterocyte-derived dipeptidyl peptidase-4 differentially regulates triglyceride excursion in mice. <i>JCI Insight</i> , 2020, 5, .	5.0	7
20	Physiological roles of the GIP receptor in murine brown adipose tissue. <i>Molecular Metabolism</i> , 2019, 28, 14-25.	6.5	36
21	Distinct Neural Sites of GLP-1R Expression Mediate Physiological versus Pharmacological Control of Incretin Action. <i>Cell Reports</i> , 2019, 27, 3371-3384.e3.	6.4	64
22	Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters. <i>Cells</i> , 2019, 8, 252.	4.1	33
23	The brown adipose tissue glucagon receptor is functional but not essential for control of energy homeostasis in mice. <i>Molecular Metabolism</i> , 2019, 22, 37-48.	6.5	56
24	Circulating Levels of Soluble Dipeptidyl Peptidase-4 Are Dissociated from Inflammation and Induced by Enzymatic DPP4 Inhibition. <i>Cell Metabolism</i> , 2019, 29, 320-334.e5.	16.2	99
25	Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2. <i>Current Opinion in Lipidology</i> , 2018, 29, 95-103.	2.7	23
26	Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism. <i>Peptides</i> , 2018, 100, 158-164.	2.4	36
27	Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction. <i>Cell Metabolism</i> , 2018, 27, 450-460.e6.	16.2	56
28	GLP-1 Receptor Expression Within the Human Heart. <i>Endocrinology</i> , 2018, 159, 1570-1584.	2.8	154
29	The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice. <i>Molecular Metabolism</i> , 2017, 6, 1339-1349.	6.5	63
30	Cellular Sites and Mechanisms Linking Reduction of Dipeptidyl Peptidase-4 Activity to Control of Incretin Hormone Action and Glucose Homeostasis. <i>Cell Metabolism</i> , 2017, 25, 152-165.	16.2	79
31	Citrus Flavonoids as Regulators of Lipoprotein Metabolism and Atherosclerosis. <i>Annual Review of Nutrition</i> , 2016, 36, 275-299.	10.1	167
32	TCF1 links GIPR signaling to the control of beta cell function and survival. <i>Nature Medicine</i> , 2016, 22, 84-90.	30.7	108
33	Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat-Fed Diabetic Mice. <i>Diabetes</i> , 2016, 65, 742-754.	0.6	82
34	Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors. <i>Endocrine Reviews</i> , 2014, 35, 992-1019.	20.1	439
35	Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection. <i>Molecular Metabolism</i> , 2014, 3, 507-517.	6.5	102
36	Naringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in Ldlr mice. <i>Journal of Lipid Research</i> , 2013, 54, 711-724.	4.2	109

#	ARTICLE	IF	CITATIONS
37	Protection from Metabolic Dysregulation, Obesity, and Atherosclerosis by Citrus Flavonoids: Activation of Hepatic PGC1 α -Mediated Fatty Acid Oxidation. <i>PPAR Research</i> , 2012, 2012, 1-9.	2.4	33
38	Citrus Flavonoids and the Prevention of Atherosclerosis. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2012, 12, 84-91.	0.7	37
39	How can nobiletin prevent obesity?. <i>Expert Review of Endocrinology and Metabolism</i> , 2011, 6, 501-503.	2.4	2
40	Nobiletin Attenuates VLDL Overproduction, Dyslipidemia, and Atherosclerosis in Mice With Diet-Induced Insulin Resistance. <i>Diabetes</i> , 2011, 60, 1446-1457.	0.6	160
41	Antiatherogenic properties of flavonoids: Implications for cardiovascular health. <i>Canadian Journal of Cardiology</i> , 2010, 26, 17A-21A.	1.7	154
42	Naringenin Decreases Progression of Atherosclerosis by Improving Dyslipidemia in High-Fat-Fed Low-Density Lipoprotein Receptor-Null Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 742-748.	2.4	141
43	Naringenin Prevents Dyslipidemia, Apolipoprotein B Overproduction, and Hyperinsulinemia in LDL Receptor-Null Mice With Diet-Induced Insulin Resistance. <i>Diabetes</i> , 2009, 58, 2198-2210.	0.6	254